2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
3
Carcinoma, Hepatocellular
3
Prostatic Neoplasms
2
Breast Neoplasms
2
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Ototoxicity
1
Heart Failure
1
Endometrial Neoplasms
1
Endometrial Hyperplasia
1
Cardiovascular Diseases
1
Cardiotoxicity
1
Atherosclerosis
1
Interventions
Echocardiography
4
sacubitril and valsartan sodium hydrate drug combination
3
Standard of Care
3
Nutrition Assessment
3
Exercise
3
Electrocardiography
3
Carvedilol
3
dapagliflozin
2
Surveys and Questionnaires
2
Spironolactone
2
Rituximab
2
Lenalidomide
2
Ivabradine
2
Control Groups
2
Blood Specimen Collection
2
Atorvastatin
2
Adrenergic beta-Antagonists
2
ziprasidone
1
pertuzumab
1
pegfilgrastim
1
obinutuzumab
1
nicotinamide-beta-riboside
1
empagliflozin
1
candesartan
1
acalabrutinib
1
Zolpidem
1
Watchful Waiting
1
Warfarin
1
Vincristine
1
Vecuronium Bromide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Heart Failure
×
Hydroxymethylglutaryl-CoA Reductase Inhibitors
×
Clear all
NCT03186404
2022-02-08
SPARE-HF
University Health Network, Toronto
Phase 2
Unknown
112 enrolled